These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34007365)

  • 1. Opioid Use in Adults With Sickle Cell Disease Hospitalized During Vaso-Occlusive Crisis: A Systematic Review.
    Osborne JC; Osakwe Z; Odlum M
    J Hematol; 2021 Apr; 10(2):46-52. PubMed ID: 34007365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IF IM in a crisis: Intranasal fentanyl versus intravenous morphine in adult vaso-occlusive crisis.
    Assad O; Zamora R; Brown K; Melnitsky L; Moses J; Sherman V
    Am J Emerg Med; 2023 Feb; 64():86-89. PubMed ID: 36481614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Vaso-Occlusive Crises and Opioid Prescriptions Among Patients with Sickle Cell Disease: A Retrospective Claims-Based Study.
    Kang HA; Barner JC; Richards KM; Bhor M; Paulose J; Kutlar A
    J Health Econ Outcomes Res; 2020; 7(1):94-101. PubMed ID: 36873574
    [No Abstract]   [Full Text] [Related]  

  • 4. Association between Vaso-occlusive Crises and Opioid Prescriptions among Patients with Sickle Cell Disease: A Retrospective Claims-based Study.
    Kang HA; Barner JC; Richards KM; Bhor M; Paulose J; Kutlar A
    J Health Econ Outcomes Res; 2020; 7(1):94-101. PubMed ID: 32685602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ketamine for Sickle Cell Vaso-Occlusive Crises: A Systematic Review.
    Alshahrani MS; Alghamdi MA
    Saudi J Med Med Sci; 2021; 9(1):3-9. PubMed ID: 33519337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid Use in Patients With Sickle Cell Disease During a Vaso-Occlusive Crisis: A Systematic Review.
    Arzoun H; Srinivasan M; Sahib I; Fondeur J; Escudero Mendez L; Hamouda RK; Mohammed L
    Cureus; 2022 Jan; 14(1):e21473. PubMed ID: 35106256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease.
    Kang HA; Barner JC
    J Manag Care Spec Pharm; 2020 Nov; 26(11):1412-1422. PubMed ID: 33119448
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of Individualized Pain Plans for Children With Sickle Cell Disease Admitted for Vaso-occlusive Crisis at Riley Hospital for Children.
    Arends AM; Perez A; Wilder C; Jacob SA
    J Pediatr Pharmacol Ther; 2022; 27(4):312-315. PubMed ID: 35558343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous Fluid Administration and the Risk of Adverse Outcomes in Sickle Cell Disease Patients Hospitalized for Vaso-Occlusive Crisis.
    Ojo AS; Ojukwu S; Asmare W; Odipe O; Larbi D
    J Hematol; 2022 Oct; 11(5):159-166. PubMed ID: 36406833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic Review of l-glutamine for Prevention of Vaso-occlusive Pain Crisis in Patients with Sickle Cell Disease.
    Cieri-Hutcherson NE; Hutcherson TC; Conway-Habes EE; Burns BN; White NA
    Pharmacotherapy; 2019 Nov; 39(11):1095-1104. PubMed ID: 31505045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and Laboratory Predictors of Painful Vaso-Occlusive Crisis Among Sickle Cell Disease Patients: A Single-Center Study in Saudi Arabia.
    Zakaria O; Buhalim RA; Almulhim F; Al Jabr FA; Alrashid A; Almutairi M
    Cureus; 2021 May; 13(5):e14980. PubMed ID: 34123674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is morphine exposure associated with acute chest syndrome in children with vaso-occlusive crisis of sickle cell disease? A 6-year case-crossover study.
    Finkelstein Y; Schechter T; Garcia-Bournissen F; Kirby M; Nurmohamed L; Juurlink DN; Blanchette V; Koren G
    Clin Ther; 2007 Dec; 29(12):2738-43. PubMed ID: 18201591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. State of the Art Management of Acute Vaso-occlusive Pain in Sickle Cell Disease.
    Puri L; Nottage KA; Hankins JS; Anghelescu DL
    Paediatr Drugs; 2018 Feb; 20(1):29-42. PubMed ID: 28853040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rates of Opioid Misuse Amongst Patients Receiving Pain Management for Sickle Cell Disease in An Urban Setting.
    Ahmed N; Okany N; Singh D; Rungkitwattanakul D; Weaver SB
    J Pharm Pract; 2024 Feb; 37(1):104-109. PubMed ID: 36120980
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of Parenteral Opioid Dosing in Adult Sickle Cell Disease Patients With Vaso-occlusive Crisis.
    Shah SP; Twilla JD; Kemp L; Phelps GL; Reaves A
    J Pain Palliat Care Pharmacother; 2018 Dec; 32(4):201-207. PubMed ID: 30896312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant interventions with opioids for vaso-occlusive crisis in sickle cell disease: A mixed treatment network meta-analysis of randomized controlled clinical trials.
    Sridharan K; Sivaramakrishnan G
    J Opioid Manag; 2020; 16(4):267-275. PubMed ID: 32885834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized Trial of Yoga for Children Hospitalized With Sickle Cell Vaso-Occlusive Crisis.
    Moody K; Abrahams B; Baker R; Santizo R; Manwani D; Carullo V; Eugenio D; Carroll A
    J Pain Symptom Manage; 2017 Jun; 53(6):1026-1034. PubMed ID: 28192225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state.
    Sins JWR; Schimmel M; Luken BM; Nur E; Zeerleder SS; van Tuijn CFJ; Brandjes DPM; Kopatz WF; Urbanus RT; Meijers JCM; Biemond BJ; Fijnvandraat K
    J Thromb Haemost; 2017 Jul; 15(7):1392-1402. PubMed ID: 28457019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic Resonance Imaging Assessment of Kidney Oxygenation and Perfusion During Sickle Cell Vaso-occlusive Crises.
    Deux JF; Audard V; Brugières P; Habibi A; Manea EM; Guillaud-Danis C; Godeau B; Galactéros F; Stehlé T; Lang P; Grimbert P; Audureau E; Rahmouni A; Bartolucci P
    Am J Kidney Dis; 2017 Jan; 69(1):51-59. PubMed ID: 27663041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease.
    Han J; Saraf SL; Gordeuk VR
    Pharmacotherapy; 2020 Jun; 40(6):535-543. PubMed ID: 32350885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.